SA
VRTX icon

Scarborough Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Scarborough Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47
Closed -$21K – 682
2026
Q1 		$21K Hold
47
– – ﹤0.01% 338
2025
Q4 		$21.4K Buy
47
+3
+7% +$1.29K ﹤0.01% 195
2025
Q3 		$17.3K Hold
44
– – ﹤0.01% 218
2025
Q2 		$19.6K Buy
+44
New +$20.3K ﹤0.01% 202
2024
Q3 		– Sell
-15
Closed -$7.03K – 438
2024
Q2 		$7.03K Hold
15
– – ﹤0.01% 229
2024
Q1 		$6.27K Buy
15
+1
+7% +$423 ﹤0.01% 239
2023
Q4 		$5.7K Buy
+14
New +$5.17K ﹤0.01% 462

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Scarborough Advisors's VRTX Position: Q2 2026 in Review

Scarborough Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 47 shares — an estimated $21K sold.

Scarborough Advisors first reported a position in VRTX in Q4 2023 and held it in 7 quarters. The position peaked at $21.4K in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Scarborough Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 47 Vertex Pharmaceuticals shares in Q2 2026, an estimated $21K.
  • Scarborough Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Scarborough Advisors's Vertex Pharmaceuticals position peaked at $21.4K in Q4 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.